the new generation glocalized network in theragenomic and personalized medicine and the genetics of patient's individualized drug safety
November 24, 2017 – New research indicates that one-size treatment for one form of blood cancer likely does not fit all, particularly when it comes to ethnic differences of patients. Â Thus, African-American men are three times more likely to be …
Cancer is not like cancer: Ethnic background matters Read more »
September 2, 2017 – The American Food & Drug Administration (FDA) has announced that two clinical trials with Pembrolizumab (Keytruda) in patients with multiple myeloma have been put on hold. The FDA informs the public, health care professionals, and oncology …
Pembrolizumab (Keytruda): Clinical trials on hold Read more »
December 02, 2015 – The American Food and Drug Administration (FDA) just granted approval for Elotuzumab (Empliciti) in combination with two other therapies to treat people with multiple myeloma who have received one to three prior medications. Elotuzumab (Empliciti) is a monoclonal …
November 21, 2015 – During the last few days, the American Food and Drug Administration  (FDA) just extended the armamentarium in the fight against multiple myeloma by two new entries, namely Ixazomib (Ninlaro) and Daratumumab (Darzalex). Both drugs are intended to treat …
![Panobinostat [Farydak] for the treatment of multiple myeloma approved](https://thasso.com/wp-content/uploads/2015/02/Multiple-Myeloma-Eye-Signs.png)
February 23, 2015 –Â Multiple myeloma is a form of blood cancer that arises from plasma cells, a type of white blood cell, found in bone marrow. According to the National Cancer Institute, approximately 21,700 Americans are diagnosed with multiple myeloma …
Panobinostat [Farydak] for the treatment of multiple myeloma approved Read more »